Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TC/AZT vs ddI or ddI/AZT in Symptomatic HIV-1 Infected Children
NCT00001066Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Jan 2001
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of lamivudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Efficacy of lamivudine and zidovudine in combination versus didanosine monotherapy or didanosine/zidovudine combination at 24 months and Safety and tolerance of 3TC/AZT at 24 months. Status: completed.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001066.